180 Life Sciences Corp (ATNF) - Total Liabilities
Based on the latest financial reports, 180 Life Sciences Corp (ATNF) has total liabilities worth $564.18 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
180 Life Sciences Corp - Total Liabilities Trend (2016–2024)
This chart illustrates how 180 Life Sciences Corp's total liabilities have evolved over time, based on quarterly financial data. See how liquid is 180 Life Sciences Corp's working capital to evaluate short-term liquidity relative to the company's equity base.
180 Life Sciences Corp Competitors by Total Liabilities
The table below lists competitors of 180 Life Sciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tianjin You Fa Steel Pipe Group Stock Co Ltd
SHG:601686
|
China | CN¥19.30 Billion |
|
DLG Exhibitions & Events Corp Ltd
SHG:600826
|
China | CN¥1.20 Billion |
|
Newonder Special Electric Co.Ltd
SHE:301120
|
China | CN¥137.45 Million |
|
Taiyuan Heavy Industry Co Ltd
SHG:600169
|
China | CN¥26.57 Billion |
|
Country Garden Holdings Company Limited
F:DZJ
|
Germany | €767.86 Billion |
|
Under Armour Inc A
NYSE:UAA
|
USA | $3.19 Billion |
|
ORION Holdings Corp
KO:001800
|
Korea | ₩1.03 Trillion |
|
Hana Microelectronics Public Company Limited
BK:HANA
|
Thailand | ฿4.81 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down 180 Life Sciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ATNF market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.56 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how 180 Life Sciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for 180 Life Sciences Corp (2016–2024)
The table below shows the annual total liabilities of 180 Life Sciences Corp from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.51 Million | -34.82% |
| 2023-12-31 | $5.39 Million | -35.14% |
| 2022-12-31 | $8.31 Million | -64.49% |
| 2021-12-31 | $23.39 Million | -7.35% |
| 2020-12-31 | $25.25 Million | +89.63% |
| 2019-12-31 | $13.31 Million | +45.72% |
| 2018-12-31 | $9.14 Million | +115.83% |
| 2017-12-31 | $4.23 Million | +1840.82% |
| 2016-12-31 | $218.11K | -- |
About 180 Life Sciences Corp
180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases in the United States. The company product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical t… Read more